ANSWER: B

Rationale:

The correct answer is B. The fundamental safety of IV PCA in opioid-naive patients rests on its self-limiting design: a patient who becomes too sedated to press the demand button cannot administer additional doses. This biological feedback mechanism is absent with continuous basal infusions, which deliver opioid regardless of the patient's level of consciousness or respiratory status. In opioid-naive patients, basal infusions have been associated with increased respiratory depression events and are contraindicated as standard practice.

• Option A: Option A incorrectly frames overnight comfort as a justification that overrides the safety concern — preventing pain awakening is not a valid indication for a basal infusion in an opioid-naive patient.
• Option C: Option C is incorrect because naloxone availability does not prevent respiratory depression from occurring; it is a rescue agent, not a preventive strategy, and its presence does not make a contraindicated practice safe.
• Option D: Option D is incorrect because extending the demand interval addresses lockout frequency, not the hazard introduced by a continuous basal infusion, which delivers opioid independent of demand dose timing.
• Option E: Option E is incorrect because the contraindication for basal infusion in opioid-naive patients is not restricted to those with OSA (obstructive sleep apnea); it applies to all opioid-naive patients because the self-limiting mechanism is absent in any patient who cannot reliably press the demand button.

ANSWER: D

Rationale:

The correct answer is D. Gabapentinoids including pregabalin and gabapentin have been incorporated into multimodal postoperative analgesic regimens for their opioid-sparing properties, reducing total opioid consumption through mechanisms involving inhibition of voltage-gated calcium channels and reduction of central sensitization. However, accumulating evidence has identified an important safety signal: gabapentinoids potentiate respiratory depression when combined with opioids, and this risk is disproportionately elevated in patients with obstructive sleep apnea (OSA), where baseline ventilatory reserve is already compromised. This patient's history of heavy snoring and witnessed apneic episodes represents a strong clinical indicator of undiagnosed OSA, making the addition of pregabalin to an opioid-containing regimen a decision that requires careful risk-benefit assessment and heightened monitoring rather than routine addition.

• Option A: Option A is incorrect because gabapentinoids are not categorically contraindicated in postoperative patients; they are used widely in multimodal regimens and the concern is patient-specific, not universal.
• Option B: Option B is incorrect and inverts the clinical reality — suspected OSA is a reason for caution with gabapentinoids, not a specific indication for them.
• Option C: Option C is incorrect because it dismisses a real and documented respiratory risk; the combination of gabapentinoids and opioids carries a meaningful increase in respiratory depression events, particularly in at-risk populations.
• Option E: Option E is incorrect because gabapentinoids do not provide sufficient analgesia to replace opioid PCA for moderate-to-severe postoperative pain, and eliminating the opioid entirely is not a practical management strategy in this clinical context.

ANSWER: A

Rationale:

The correct answer is A. IV morphine was historically used in acute pulmonary edema for its dual benefit of preload reduction through venodilatation and relief of dyspnea-associated distress through central opioid receptor activity. However, a large registry analysis and subsequent observational studies associated IV morphine use in acute decompensated heart failure with significantly higher in-hospital mortality, even after adjustment for clinical confounders. The proposed mechanism for harm includes respiratory depression superimposed on already-compromised pulmonary function, nausea and vomiting with aspiration risk, and potential hemodynamic instability. As a result, most current heart failure guidelines have downgraded or removed the recommendation for routine IV morphine in acute pulmonary edema, reserving it at most for patients with refractory symptoms in whom the benefit of comfort is judged to outweigh risk.

• Option B: Option B is incorrect because it describes the historical position that current evidence has undermined — IV morphine is not a recommended first-line agent in contemporary acute heart failure management, and no survival benefit has been demonstrated.
• Option C: Option C is incorrect because the evidence concern about morphine in acute heart failure is not limited to patients without concurrent MI; the registry data showing increased mortality applied broadly to the acute decompensated heart failure population.
• Option D: Option D is incorrect because the concern about IV morphine in acute heart failure is not primarily about renal morphine-6-glucuronide (M6G) accumulation — it is about acute hemodynamic and respiratory effects in the setting of decompensated ventricular function.
• Option E: Option E is incorrect and directly contradicts the post-registry reassessment that shifted guideline recommendations away from routine morphine use in this setting.

ANSWER: C

Rationale:

The correct answer is C. Intranasal fentanyl has been increasingly recognized as an effective and needle-free analgesic option for acute pediatric pain, including trauma, when IV access is not yet available. Fentanyl's high lipophilicity allows rapid absorption through the nasal mucosa, producing meaningful analgesia within minutes without the distress of venipuncture — a significant practical advantage in a frightened, uncooperative child. Multiple pediatric emergency studies have demonstrated its efficacy and safety for acute fracture pain.

• Option A: Option A is incorrect because withholding analgesia while attempting IV placement in a child with a displaced fracture is both ethically inappropriate and practically counterproductive — adequate analgesia facilitates cooperation with subsequent procedures including IV placement itself.
• Option B: Option B is incorrect because oral oxycodone does not provide rapid analgesia; oral opioids require gastrointestinal absorption and have onset times of 30–45 minutes, making them unsuitable for immediate acute pain relief. Additionally, gastric emptying may be delayed in a stressed, injured child.
• Option D: Option D is incorrect because intramuscular injection, while capable of delivering opioid without IV access, requires a needle and is particularly distressing in pediatric patients; it is not the preferred route when a non-needle alternative is available and effective.
• Option E: Option E is incorrect because sublingual buprenorphine is not a standard acute trauma analgesic in pediatric patients, has a slower titration profile than fentanyl for acute pain, and is not recognized as a first-line agent in this context.

ANSWER: E

Rationale:

The correct answer is E. The standard convention for breakthrough dosing in cancer pain management is to prescribe 10–15% of the total 24-hour opioid dose as each breakthrough dose, available every 1–4 hours as needed. For this patient receiving 120 mg morphine per day, 10–15% equals 12–18 mg per breakthrough dose — appropriately represented in Option E. This formula is grounded in the pharmacokinetic relationship between the maintenance dose and the dose increment needed to meaningfully raise plasma opioid concentration above the baseline analgesic level. The 1–4 hour availability window reflects the duration of action of immediate-release oral morphine and allows reassessment before repeat dosing.

• Option A: Option A is incorrect because a fixed 5 mg dose is not calibrated to this patient's demonstrated opioid tolerance — it represents a starting dose for an opioid-naive patient and would be entirely subtherapeutic for someone already receiving 120 mg/day.
• Option B: Option B is incorrect because matching the extended-release dose (60 mg) as a breakthrough dose would represent 50% of the total daily dose per rescue dose — a dangerously excessive amount.
• Option C: Option C is incorrect because 30 mg represents one-quarter (25%) of the total daily dose, substantially exceeding the 10–15% guideline and creating significant overdose risk with multiple breakthrough doses.
• Option D: Option D is incorrect because 120 mg as a single breakthrough dose equals the entire 24-hour scheduled dose — this would represent a catastrophic overdose.

ANSWER: B

Rationale:

The correct answer is B. The standard WHO-based titration rule for cancer pain management specifies that when a patient consistently requires more than three to four breakthrough doses per day, the around-the-clock (ATC) dose should be increased. The method for calculating the new baseline is to add the total opioid used for breakthrough doses in the past 24 hours to the current scheduled daily dose, then redistribute that total as the new extended-release regimen. This patient used five breakthrough doses; at approximately 18–27 mg each, she used roughly 90–135 mg in rescue doses — this amount should be added to her 180 mg/day baseline to establish her new ATC dose, with a new 10–15% breakthrough dose calculated on the revised total.

• Option A: Option A is incorrect because shortening the breakthrough interval to every 30 minutes without adjusting the baseline dose does not address the underlying problem of inadequate around-the-clock analgesia and creates risk of cumulative dose toxicity.
• Option C: Option C is incorrect because there is no threshold of daily breakthrough dose use that automatically mandates transition to intrathecal delivery; intrathecal drug delivery systems are indicated for refractory pain or intolerable systemic adverse effects, not for patients who simply require breakthrough doses more than twice daily.
• Option D: Option D is incorrect because reducing the ATC dose moves in the wrong direction — the clinical data indicate the baseline is insufficient, not excessive.
• Option E: Option E is incorrect because a 7-day wait without dose adjustment in a cancer patient requiring five breakthrough doses per day represents inadequate pain management; the WHO guideline recommends reassessment within 24–48 hours of any dose change and prompt escalation when breakthrough use indicates undertreated baseline pain.

ANSWER: D

Rationale:

The correct answer is D. This presentation — sudden severe back pain with bilateral radicular distribution, new limb weakness, and urinary dysfunction — is the classic triad of malignant spinal cord compression (SCC), a true oncological emergency in which hours matter for preservation of neurological function. The cornerstone of immediate pharmacological management is high-dose corticosteroids, most commonly dexamethasone, which reduces perilesional edema and partially decompresses the cord while definitive treatment is arranged. Parallel to corticosteroid administration, emergency radiation oncology or neurosurgical consultation must be obtained immediately, as surgical decompression or radiotherapy are the definitive treatments that determine whether ambulatory function is preserved. Opioid analgesia is appropriate for immediate pain control but does not address the underlying compressive pathology.

• Option A: Option A is incorrect because opioid dose escalation and outpatient MRI in 72 hours represent a dangerous underreaction to neurological emergency; the window for preserving function closes within hours of cord compression onset.
• Option B: Option B is incorrect because ketorolac addresses inflammatory pain and has no role in cord decompression; a one-week radiotherapy timeline in acute SCC would result in irreversible neurological deficits.
• Option C: Option C is incorrect because malignant SCC is treatable and reversible if addressed promptly — initiating hospice for a patient with new SCC without a decompression attempt represents a failure of appropriate emergency oncological management.
• Option E: Option E is incorrect because epidural steroid injection is not indicated for malignant cord compression from metastatic disease; it is used for degenerative inflammatory spinal conditions, and injecting into a metastatically involved epidural space risks tumor seeding and acute decompensation.

ANSWER: A

Rationale:

The correct answer is A. Visceral pain from malignant bowel obstruction requires a multicomponent pharmacological approach that addresses the distinct mechanisms contributing to the symptom burden. Opioids are the cornerstone for visceral nociceptive pain but do not address the secretory and peristaltic components that drive colicky pain, nausea, and vomiting. Anticholinergic agents such as hyoscine butylbromide (scopolamine butylbromide) reduce smooth muscle spasm and GI secretions, directly addressing the cramping component and decreasing the volume of intestinal secretions that accumulate proximal to the obstruction. Octreotide, a somatostatin analogue, reduces GI secretion and motility through inhibition of multiple secretory peptides, providing significant reduction in obstruction-related nausea, vomiting, and colicky pain. This three-agent combination — opioid, anticholinergic, octreotide — represents the pharmacological standard for inoperable malignant bowel obstruction in palliative care.

• Option B: Option B is incorrect because NSAIDs do not effectively address visceral pain from mechanical obstruction; their anti-inflammatory mechanism is not relevant to the colicky pain of bowel obstruction, and high-dose scheduled NSAIDs in a patient with advanced cancer carry significant GI and renal toxicity risks.
• Option C: Option C is incorrect because opioids alone leave the secretory, cramping, and motility components of obstruction-related pain inadequately treated; adjuvant agents provide complementary mechanisms that meaningfully improve symptom control beyond what opioids achieve alone.
• Option D: Option D is incorrect because corticosteroids are not analgesics for bowel obstruction pain, and laxatives in a complete mechanical obstruction are contraindicated and potentially dangerous.
• Option E: Option E is incorrect because malignant bowel obstruction pain is visceral-nociceptive in character, not primarily neuropathic, and gabapentinoids are not recognized as effective agents for this pain mechanism or this clinical context.

ANSWER: C

Rationale:

The correct answer is C. The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain specifies two key morphine milligram equivalent (MME) thresholds for chronic non-cancer pain: doses at or above 50 MME/day are associated with substantially increased overdose risk compared to lower doses, and doses at or above 90 MME/day are associated with very high overdose risk and should be avoided or prescribed only after careful individualized reassessment. This patient's current dose of approximately 105 MME/day exceeds both thresholds and falls squarely in the very high-risk category, warranting a deliberate reassessment of the risk-benefit balance, exploration of opioid-sparing strategies, and a collaborative conversation about potential dose reduction.

• Option A: Option A is incorrect because no clinical guidelines characterize doses in the 90–120 MME/day range as low-risk; 105 MME/day exceeds the guideline's very high-risk threshold.
• Option B: Option B is incorrect because the 2022 CDC guideline identifies 50 MME/day as the lower threshold for substantially elevated risk and 90 MME/day as the very high-risk threshold — not 120 MME/day.
• Option D: Option D is incorrect because the 2022 guideline does provide specific MME numerical thresholds as part of its evidence-based recommendations, though it frames them as risk stratification tools rather than absolute prescribing limits.
• Option E: Option E is incorrect and importantly so: the 2022 CDC guideline explicitly emphasizes a non-coercive, patient-centered approach to dose reduction and specifically states that abrupt discontinuation or rapid forced tapering without patient collaboration is associated with harm. The guideline recommends reassessment and collaborative planning, not mandated immediate tapering.

ANSWER: E

Rationale:

The correct answer is E. The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain explicitly identifies the concurrent prescribing of opioids and benzodiazepines as a particularly high-risk combination that should be avoided when possible. Both drug classes produce central nervous system (CNS) depression and respiratory depression through pharmacologically distinct but additive or synergistic mechanisms — opioids through mu-opioid receptor (MOR)-mediated suppression of respiratory drive in the brainstem, and benzodiazepines through potentiation of gamma-aminobutyric acid A (GABAA) receptor-mediated inhibition. Epidemiological data consistently show that patients receiving both classes have substantially higher rates of overdose death than those receiving either drug class alone. The increased daytime sedation this patient reports is a clinical warning sign that CNS depression is already occurring. The appropriate response is collaborative reassessment of whether both drug classes are truly necessary, exploration of non-benzodiazepine alternatives for anxiety, and if both are continued, heightened monitoring and co-prescription of naloxone.

• Option A: Option A is incorrect because the CDC guideline does not identify a safe threshold of benzodiazepine dose that removes the elevated risk when combined with opioids — the concern is the combination itself, not a specific benzodiazepine dose ceiling.
• Option B: Option B is incorrect because the guideline's concern about opioid-benzodiazepine co-prescribing is not contingent on an opioid dose threshold; it applies at any opioid dose, and this patient already exceeds the 90 MME/day very high-risk threshold independently.
• Option C: Option C is incorrect because the guideline's guidance goes beyond monitoring — it recommends avoiding the combination when possible, not simply monitoring for illicit use.
• Option D: Option D is incorrect and clinically dangerous; while treating anxiety can contribute to overall pain management, this framing provides a justification for a co-prescribing pattern that guidelines specifically identify as high-risk and should be avoided.

ANSWER: B

Rationale:

The correct answer is B. The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain contains an explicit and emphatic statement that abrupt discontinuation or rapid tapering of opioids imposed without patient collaboration is associated with patient harm. The documented harms include undertreated pain, opioid withdrawal syndrome (characterized by autonomic instability, severe myalgia, GI distress, and profound anxiety), and — critically — increased risk of patients turning to illicit opioids when their prescribed supply is abruptly cut off, which substantially elevates overdose mortality risk because illicit opioid supply is increasingly contaminated with fentanyl and fentanyl analogues. The guideline instead recommends a patient-centered, collaborative approach to opioid tapering that proceeds at a pace the individual patient can tolerate, which for patients on long-standing high-dose therapy may extend over months to years.

• Option A: Option A is incorrect and directly contradicts the guideline — the CDC does not recommend abrupt discontinuation at any dose threshold, and the premise that gradual tapering simply "prolongs risk" ignores the substantial harms of abrupt cessation.
• Option C: Option C is incorrect because documentation of clinical rationale does not justify abrupt discontinuation; the harm from abrupt discontinuation is not mitigated by documentation.
• Option D: Option D is incorrect because the co-presence of benzodiazepines, while increasing overall risk, does not make abrupt opioid discontinuation safer or guideline-endorsed; both medications would require careful, monitored tapering rather than abrupt cessation.
• Option E: Option E is incorrect because inability to articulate functional benefit at a single visit is not a trigger for abrupt discontinuation; it is a trigger for collaborative reassessment and a discussion about tapering goals, not immediate cessation.

ANSWER: D

Rationale:

The correct answer is D. The universal precautions framework in opioid prescribing — explicitly endorsed by the 2022 CDC guideline — applies a consistent set of monitoring and safety practices to all patients receiving opioid therapy, regardless of individual risk level, just as universal precautions in infection control apply to all patients regardless of known infectious status. Prescription Drug Monitoring Program (PDMP) review is a core component of universal precautions and should be performed at opioid initiation and at clinically appropriate intervals during ongoing therapy. PDMP review identifies concurrent prescribing from multiple providers, detects high-dose opioid prescribing patterns, and identifies dangerous co-prescribing combinations — information that is not reliably obtainable from the patient history alone.

• Option A: Option A is incorrect because urine drug screening (UDS) in the CDC's universal precautions framework is recommended both at baseline and periodically during therapy; its purpose is ongoing confirmation of adherence and detection of unprescribed substances, not a one-time assessment.
• Option B: Option B is incorrect because PDMP review under universal precautions is not restricted to high-risk patients — it is applied to all patients receiving opioids. Limiting it to high-risk patients would create a false sense of security for patients who have not been formally risk-stratified.
• Option C: Option C is incorrect because written opioid treatment agreements are a component of universal precautions and are applied across the prescribing population; the framing that universal application stigmatizes low-risk patients reflects a common prescriber concern but does not align with the guideline's recommendation.
• Option E: Option E is incorrect because universal precautions, by definition, do not have a dose threshold for application; the guideline applies its monitoring framework to all patients on opioid therapy, not only those above a specific MME threshold.

ANSWER: A

Rationale:

The correct answer is A. Precipitated withdrawal is the primary safety concern during buprenorphine induction. Buprenorphine has very high affinity for the mu-opioid receptor (MOR) — higher than most full agonist opioids including heroin and morphine — combined with partial agonist activity, meaning it produces less maximal receptor activation than a full agonist at equivalent receptor occupancy. If buprenorphine is administered while full agonist opioids are still substantially occupying mu receptors, buprenorphine competitively displaces them, abruptly reducing total receptor activation from the full agonist level to the lower partial agonist ceiling, triggering immediate and severe withdrawal. The COWS score threshold of 8–12 (corresponding to at least moderate withdrawal) serves as a clinical surrogate for sufficient endogenous opioid clearance from receptors — enough displacement has occurred that buprenorphine administration will provide net agonist relief rather than net agonist reduction. This patient's COWS of 14 meets the threshold and supports proceeding with induction.

• Option B: Option B is incorrect because a threshold of 25 (moderate-severe withdrawal) is unnecessarily high; patients at COWS 8–12 have already cleared sufficient opioid for safe induction, and requiring scores of 25 forces patients through unnecessary suffering.
• Option C: Option C is incorrect because the risk of precipitated withdrawal with early buprenorphine administration is real and clinically serious; buprenorphine does not automatically stabilize patients regardless of receptor occupancy — it can precipitate severe withdrawal if given prematurely.
• Option D: Option D is incorrect because the COWS threshold applies across opioid types, not selectively to heroin users; the mechanism of precipitated withdrawal is the same regardless of which full agonist opioid is present.
• Option E: Option E is incorrect and inverts the clinical rule — a COWS below 8 indicates insufficient withdrawal and excessive residual receptor occupancy, making buprenorphine induction at that point high-risk for precipitated withdrawal, not safe.

ANSWER: C

Rationale:

The correct answer is C. Illicitly manufactured fentanyl presents a distinctive challenge to standard buprenorphine induction protocols because of its exceptional lipophilicity and the resulting pharmacokinetic behavior of extensive tissue sequestration. Unlike heroin or prescription opioids, fentanyl accumulates in adipose and other lipophilic compartments from which it is released slowly over time, maintaining significant mu-opioid receptor occupancy long after the last dose and long after the patient reports feeling ill. This creates a clinical paradox: the patient may have a COWS score below the standard induction threshold (suggesting insufficient withdrawal) yet actually be in meaningful withdrawal, because the COWS score reflects the current opioid effect experienced rather than total receptor occupancy. If standard buprenorphine is administered at a full induction dose under these conditions, it may still precipitate severe withdrawal by displacing residual sequestered fentanyl from receptors. The Bernese protocol (micro-induction) addresses this by starting at very low sublingual doses (0.5–1 mg), which partially occupy receptors without displacing sufficient fentanyl to trigger precipitated withdrawal, and escalating progressively over 3–7 days to therapeutic doses.

• Option A: Option A is incorrect because fentanyl actually has high mu-opioid receptor affinity — its receptor affinity is not meaningfully lower than buprenorphine's in the context of tissue-sequestered drug.
• Option B: Option B is incorrect because the motivation for micro-induction is precipitated withdrawal prevention, not the eventual target dose; target doses for fentanyl users are not systematically higher than for other opioid users.
• Option D: Option D is incorrect because there is no chemical incompatibility between buprenorphine and fentanyl; they compete for the same receptor through pharmacological affinity, not chemical incompatibility.
• Option E: Option E is incorrect because buprenorphine resistance is not a recognized pharmacological phenomenon in fentanyl users; the challenge is receptor occupancy by sequestered drug, not any alteration in receptor sensitivity to buprenorphine.

ANSWER: E

Rationale:

The correct answer is E. The Drug Addiction Treatment Act (DATA) 2000 established the X-waiver system, which required prescribers to complete special training, obtain a separate DEA registration waiver, and adhere to patient number limits before prescribing buprenorphine for opioid use disorder (OUD) in office-based settings. This regulatory structure created substantial access barriers, particularly in primary care, emergency medicine, and rural practice settings where prescriber training and registration gaps were significant. The Consolidated Appropriations Act of 2023 eliminated the X-waiver requirement in its entirety, allowing any DEA-licensed prescriber to prescribe buprenorphine for OUD without a separate waiver, special registration, or mandatory training completion requirement. This change was expected to substantially expand access to medications for opioid use disorder (MOUD), particularly in primary care and rural settings. The internist in this scenario can prescribe buprenorphine for OUD using her existing DEA registration.

• Option A: Option A is incorrect because the DATA 2000 X-waiver requirement was eliminated by the Consolidated Appropriations Act of 2023; the 8-hour training requirement no longer applies as a prerequisite for prescribing.
• Option B: Option B is incorrect because there is no specialist restriction on buprenorphine prescribing for OUD; the removal of the X-waiver was specifically intended to expand access to primary care and generalist prescribers.
• Option C: Option C is incorrect because the OTP registration requirement applies to methadone dispensing for OUD, not to buprenorphine — buprenorphine can be prescribed in office-based settings, which is one of its key access advantages over methadone.
• Option D: Option D is incorrect because no mandatory 24-hour training requirement was substituted for the eliminated X-waiver; while continued education in addiction medicine is clinically valuable, it is not currently a regulatory prerequisite for buprenorphine prescribing.

ANSWER: B

Rationale:

The correct answer is B. Extended-release injectable naltrexone provides 30 days of opioid receptor blockade per injection and does not produce physical dependence. However, its most critical safety liability is what happens if a patient misses an injection or discontinues treatment: during the period of receptor blockade, opioid tolerance diminishes because the receptors are not being activated. When the naltrexone effect wanes or if the patient attempts to override the blockade by using large opioid doses, they are effectively opioid-naive from a tolerance standpoint. Any opioid use at or near the doses the patient used prior to naltrexone initiation will now produce a dramatically amplified effect, creating acute overdose risk that can be rapidly fatal. Patients and their support networks must receive specific, concrete counseling on this risk and must understand that discontinuing naltrexone without transitioning to other treatment is a high-risk decision requiring immediate clinical planning.

• Option A: Option A is incorrect because naltrexone-induced mu-opioid receptor (MOR) blockade is reversible; receptors return to normal function after naltrexone clearance, and there is no permanent downregulation.
• Option C: Option C is incorrect because naltrexone is a pure opioid antagonist that does not produce physical dependence — there is no opioid withdrawal syndrome upon its discontinuation. Patients may experience symptoms of unmasked opioid craving, but this is not pharmacological withdrawal from naltrexone itself.
• Option D: Option D is incorrect in its framing: while naltrexone can be hepatotoxic at very high doses (far above clinical doses), the prescribing information recommends baseline liver function testing and monitoring, but weekly testing for three months is not the standard protocol and overstates the hepatic risk profile at therapeutic doses.
• Option E: Option E is incorrect because naltrexone reduces but does not eliminate opioid craving, and no pharmacological treatment for OUD is effective as monotherapy without concurrent psychosocial support; naltrexone has the lowest treatment retention rates among the three approved MOUD options and particularly requires behavioral support to maintain adherence.

ANSWER: D

Rationale:

The correct answer is D. Meperidine (pethidine) is absolutely contraindicated in elderly patients and represents one of the clearest opioid contraindications in clinical medicine. Meperidine undergoes hepatic metabolism to normeperidine, an active metabolite with a half-life of 15–20 hours (far longer than meperidine itself at 3–5 hours) that is renally excreted. In elderly patients, reduced renal clearance — compounded in this patient by stage 3 chronic kidney disease — causes normeperidine to accumulate with repeated dosing. Unlike meperidine itself, normeperidine does not produce analgesia; it is a CNS excitatory compound that produces dysphoria, tremors, myoclonus, and seizures. Because normeperidine-induced seizures are not reversed by naloxone (it is not an opioid-receptor-mediated effect), they require benzodiazepine treatment and can be difficult to control. Meperidine appears on the American Geriatrics Society Beers Criteria as a medication to avoid in older adults. Option A is partially correct in noting that hydromorphone-3-glucuronide (H3G) accumulates in renal impairment; however, H3G does not cause respiratory depression — it causes neuroexcitatory effects — and hydromorphone is not absolutely contraindicated but requires dose adjustment and close monitoring in renal impairment, making it a manageable choice rather than an absolute contraindication.

• Option B: Option B is incorrect because while CYP2D6 (cytochrome P450 2D6) variability affects codeine and to a lesser degree tramadol, oxycodone's primary metabolic pathway includes multiple routes and it is not absolutely contraindicated by age-related CYP2D6 changes.
• Option C: Option C is incorrect because elderly patients typically have decreased body fat and volume of distribution for lipophilic drugs, not increased accumulation; transdermal fentanyl requires careful titration in elderly patients but is not absolutely contraindicated.
• Option E: Option E is incorrect and overstated; while morphine-6-glucuronide (M6G) accumulation in renal impairment is a genuine concern requiring dose reduction and monitoring, oral morphine is not invariably fatal in patients over 70 at appropriate reduced doses.

ANSWER: A

Rationale:

The correct answer is A. The pharmacological basis for dose reduction in elderly patients is multifactorial and operates through both pharmacokinetic and pharmacodynamic mechanisms. Pharmacokinetically, reduced renal clearance leads to accumulation of active opioid metabolites (morphine-6-glucuronide (M6G), normeperidine, hydromorphone-3-glucuronide (H3G)); reduced hepatic blood flow decreases first-pass metabolism and increases the oral bioavailability of high-extraction opioids; decreased albumin and alpha-1-acid glycoprotein alter protein binding and free drug fractions; and altered body composition (decreased lean mass and body water) changes volumes of distribution. Pharmacodynamically — and critically — elderly patients demonstrate increased CNS sensitivity to opioids at equivalent plasma concentrations, likely reflecting reduced neuronal density, changes in receptor expression, and decreased neurotransmitter reserve. The net effect is that equivalent plasma opioid concentrations produce greater analgesia and greater adverse effects, including sedation, respiratory depression, cognitive impairment, and falls. The clinical summary is a 25–50% dose reduction with more frequent reassessment — "start low, go slow."

• Option B: Option B is incorrect because elderly patients do not have higher total body water; the opposite is true. Aging is associated with decreased lean muscle mass, decreased total body water, and for lipophilic drugs, potentially decreased volume of distribution, not increased.
• Option C: Option C is incorrect because mu-opioid receptor density does not decline to the point of opioid ineffectiveness with normal aging; opioids remain effective analgesics in elderly patients and are frequently appropriate when used at adjusted doses.
• Option D: Option D is incorrect because while decreased GI motility can affect absorption kinetics for oral agents, this is not the primary or complete explanation for the lower dose requirement; the pharmacodynamic increase in CNS sensitivity is a critical independent component.
• Option E: Option E is incorrect because the dose reduction need in elderly patients is not explained solely by renal function; even elderly patients with well-preserved renal function demonstrate increased pharmacodynamic opioid sensitivity and require careful dose adjustment.

ANSWER: C

Rationale:

The correct answer is C. Morphine is classified as a high-hepatic-extraction drug, meaning that under normal circumstances a large fraction of an oral dose is metabolized during first-pass transit through the liver before reaching the systemic circulation — resulting in oral bioavailability of approximately 20–40% in healthy adults. In hepatic impairment, particularly at the Child-Pugh B or C level, hepatic blood flow is reduced and the enzymatic capacity for first-pass metabolism is impaired. The consequence for oral morphine is that a greater fraction of the administered dose bypasses first-pass metabolism and reaches the systemic circulation intact, producing significantly higher plasma concentrations than the same dose would generate in a patient with normal liver function. This bioavailability increase is clinically important: a patient with cirrhosis started on the same oral morphine dose used in healthy adults may experience an unexpected overdose effect. The appropriate response is to start at substantially lower oral doses, extend the dosing interval, and monitor closely for signs of accumulation.

• Option A: Option A is incorrect and inverts the mechanism — hepatic impairment reduces first-pass metabolism, which increases (not decreases) bioavailability.
• Option B: Option B is incorrect because morphine undergoes substantial hepatic glucuronidation as its primary elimination pathway; hepatic impairment meaningfully affects both its metabolism and oral bioavailability.
• Option D: Option D is incorrect because while hepatic impairment does reduce glucuronidation to morphine-6-glucuronide (M6G), morphine retains its own analgesic activity as the parent compound and at other metabolic products; it does not become pharmacologically inert, and the adverse effect profile is not eliminated but altered.
• Option E: Option E is incorrect because Child-Pugh B/C cirrhosis reduces CYP enzyme activity rather than inducing it; accelerated clearance due to CYP3A4 induction does not occur in cirrhosis.

ANSWER: E

Rationale:

The correct answer is E. Methadone presents a uniquely difficult risk profile in the setting of hepatic impairment, arising from the intersection of several pharmacological characteristics. First, methadone is extensively metabolized by CYP3A4 (cytochrome P450 3A4) — and to a lesser extent CYP2D6 and CYP2B6 — in the liver; in cirrhosis, the activity of these enzymes is highly variable and unpredictable, making standard dose calculations unreliable. Second, methadone has an exceptionally long and highly variable half-life of 8–80 hours in healthy adults, which becomes even more prolonged and unpredictable when hepatic clearance is impaired; this means that dose accumulation can occur insidiously over 3–5 days after any dose change, long after the prescriber and patient believe a steady state has been reached. Third, methadone has a narrow effective-to-toxic concentration window. The combination of unpredictable clearance, prolonged half-life, and narrow therapeutic index makes methadone the opioid most likely to produce delayed respiratory depression and cardiovascular toxicity (QTc prolongation) in patients with cirrhosis, even at doses that appear conservative at initiation.

• Option A: Option A is incorrect because hydromorphone is not CYP2D6-dependent for activity; it undergoes glucuronidation as its primary metabolic pathway and requires dose adjustment but not CYP2D6-driven activation.
• Option B: Option B is incorrect because hepatic impairment affects fentanyl through CYP3A4 clearance, not through a redistribution mechanism that preferentially increases CNS accumulation; the concern is prolonged systemic half-life, not selective CNS targeting.
• Option C: Option C is incorrect because buprenorphine's partial agonist ceiling effect is an intrinsic receptor pharmacology property — the ceiling on respiratory depression reflects its intrinsic efficacy at the mu-opioid receptor (MOR), not a hepatically mediated mechanism that can be eliminated by liver disease.
• Option D: Option D is incorrect because oxycodone is not a prodrug that requires mandatory first-pass conversion to oxymorphone for analgesic activity; oxycodone itself is analgesically active, with CYP2D6-mediated conversion to oxymorphone as a secondary pathway.

ANSWER: B

Rationale:

The correct answer is B. The historical practice of discontinuing buprenorphine preoperatively was based on the reasoning that buprenorphine's high mu-opioid receptor (MOR) affinity would competitively block full agonist analgesics postoperatively, rendering them ineffective. However, this practice is now generally discouraged by current evidence and clinical guidelines for two independent reasons. First, discontinuing buprenorphine in the perioperative period — a time of heightened psychological stress, pain, and disrupted routine — substantially increases the risk of opioid relapse, which carries far greater harm than any analgesic management challenge. Second, buprenorphine's very high MOR affinity means that even with discontinuation 24–72 hours before surgery, significant receptor occupancy persists, making the analgesic rationale for discontinuation ineffective in practice. The preferred approach is continuation of buprenorphine throughout the perioperative period, using multimodal analgesia (regional blocks, acetaminophen, NSAIDs, ketamine infusion) for surgical pain. If full agonist opioids are genuinely needed for breakthrough pain, doses substantially higher than standard may be required to overcome competitive receptor occupancy, and this should be anticipated in postoperative orders.

• Option A: Option A is incorrect because 72-hour preoperative discontinuation does not reliably clear buprenorphine from receptors — residual high-affinity occupancy persists, and the relapse risk created by discontinuation is clinically unacceptable.
• Option C: Option C is incorrect because converting to methadone is not an indicated perioperative strategy for a patient on buprenorphine maintenance; it introduces the analgesic and QTc risks of methadone without addressing the underlying management challenge.
• Option D: Option D is incorrect because attempting to saturate receptors with high-dose morphine against residual buprenorphine occupancy is clinically dangerous and not an established strategy; the doses required to displace high-affinity buprenorphine would pose severe respiratory depression risk.
• Option E: Option E is incorrect because perioperative opioid management requires active collaboration among the addiction prescriber, anesthesiologist, and surgeon; abdicating this responsibility to a single team member endangers patient safety.

ANSWER: D

Rationale:

The correct answer is D. Ketamine at sub-dissociative doses (typically 0.1–0.5 mg/kg/hour IV) exerts its primary analgesic and opioid-sparing effects through N-methyl-D-aspartate (NMDA) receptor antagonism in the dorsal horn of the spinal cord. NMDA receptor activation by glutamate and substance P plays a central role in central sensitization — the process by which repetitive nociceptive input lowers the activation threshold of dorsal horn neurons, amplifying pain perception. In opioid-tolerant patients, central sensitization is a significant contributor to both ongoing chronic pain and exaggerated postoperative pain responses; furthermore, rapidly fluctuating opioid concentrations in the perioperative period (from conversion, dose titration, and breakthrough dosing) can trigger or worsen opioid-induced hyperalgesia (OIH) through NMDA-dependent mechanisms. Ketamine infusion blocks these NMDA-mediated processes, reducing both the central sensitization component of postoperative pain and the amplification of OIH. Multiple randomized controlled trials have demonstrated reduced postoperative opioid consumption, lower pain scores, and reduced OIH in opioid-tolerant patients receiving perioperative ketamine infusions.

• Option A: Option A is incorrect because ketamine has no meaningful mu-opioid receptor agonist activity at clinical doses; its analgesic mechanism is NMDA antagonism, not opioid receptor activation.
• Option B: Option B is incorrect because the indication for sub-dissociative ketamine is analgesic and opioid-sparing, not prevention of intraoperative awareness; awareness prevention involves anesthetic depth monitoring and volatile agent dosing, not analgesic adjuncts.
• Option C: Option C is incorrect because the alpha-2 adrenergic agonist activity described belongs to dexmedetomidine, not ketamine; ketamine has some sympathomimetic properties but its analgesic mechanism is NMDA antagonism.
• Option E: Option E is incorrect because ketamine does not provide clinically significant antiemetic effects at sub-dissociative doses; it actually mildly increases nausea risk at some doses, and antiemetic prophylaxis in opioid-tolerant patients is typically provided by ondansetron or dexamethasone.

ANSWER: A

Rationale:

The correct answer is A. The perioperative PCA management of opioid-tolerant patients requires an explicit understanding of how the contraindication for basal infusions — which applies to opioid-naive patients — is reversed in the tolerant patient. In an opioid-naive patient, a basal infusion eliminates the self-limiting demand-only safety mechanism and creates respiratory depression risk. In an opioid-tolerant patient, omitting a basal infusion creates an entirely different problem: the patient's established daily opioid requirement must be met to prevent withdrawal syndrome (tachycardia, hypertension, diaphoresis, severe anxiety, muscle pain), which is both physiologically disruptive and clinically indistinguishable from hemodynamically significant surgical complications. The basal rate on the PCA is set to deliver approximately the patient's pre-hospital 24-hour opioid requirement as continuous background infusion — translated from her oral oxycodone dose to IV hydromorphone equivalent with appropriate cross-tolerance reduction. Demand doses are then programmed to manage surgical pain above and beyond the baseline. Failure to provide a basal infusion in opioid-tolerant patients produces severe undertreatment that is frequently misinterpreted as drug-seeking behavior.

• Option B: Option B is incorrect because the contraindication for basal PCA infusions applies specifically to opioid-naive patients; in opioid-tolerant patients, the basal infusion serves a physiologically necessary function.
• Option C: Option C is incorrect because demand dosing alone cannot substitute for basal coverage in a tolerant patient — the self-administration frequency required to cover both baseline and surgical requirements would be excessive and the PCA lockout intervals would prevent it.
• Option D: Option D is incorrect because the need for a basal infusion in an opioid-tolerant patient is determined by pre-existing tolerance, not by a post-hoc pain score threshold.
• Option E: Option E is incorrect because while long-term opioid therapy carries tolerance-related risks, the perioperative period is not the appropriate context to withhold baseline opioid coverage; inadequately managed perioperative pain is associated with worse outcomes than the theoretical tolerance concern in this acute setting.

ANSWER: C

Rationale:

The correct answer is C. OxyContin OP (extended-release oxycodone) was reformulated in 2010 using a polyethylene oxide (PEO) polymer matrix. When the tablet is wetted — whether by attempting to dissolve it for injection or by exposing it to moisture during crushing for insufflation — the PEO matrix swells and forms a viscous, sticky gel that resists both dissolution into an injectable solution and pulverization into an inhalable powder. This physical barrier substantially reduces the two primary non-oral abuse routes: intranasal insufflation and intravenous injection. Post-market epidemiological data confirmed a meaningful reduction in oxycodone abuse by these specific routes following the 2010 reformulation. However, the same data revealed an unintended consequence: in populations where opioid misuse was prevalent, a subset of users who could no longer misuse oxycodone by injection shifted to heroin — which was available, less expensive, and provided similar mu-opioid receptor activation. This drug substitution phenomenon illustrates that abuse-deterrent formulations can alter the route and agent of abuse without necessarily reducing total opioid use disorder burden in affected populations.

• Option A: Option A is incorrect because OxyContin OP does not contain sequestered naltrexone; that ADF mechanism is used in Embeda (extended-release morphine with a naltrexone core).
• Option B: Option B is incorrect because the osmotic release oral system (OROS) that produces a hollow shell when tampered with is the mechanism used in Exalgo (extended-release hydromorphone), not OxyContin OP.
• Option D: Option D is incorrect because bittering agents are an aversion technology used in some other ADF products but are not the primary mechanism of OxyContin OP; additionally, drug substitution effects were documented in post-market surveillance, making the second clause of this option factually wrong.
• Option E: Option E is incorrect because ADF reformulation does not reduce oral bioavailability; ADFs are specifically designed to preserve the intended oral therapeutic effect while deterring non-oral abuse routes.

ANSWER: E

Rationale:

The correct answer is E. The autonomic manifestations of opioid withdrawal — tachycardia, hypertension, diaphoresis, diarrhea, piloerection, anxiety, and mydriasis — are driven by noradrenergic hyperactivity arising from the locus coeruleus (LC), the brain's principal noradrenergic nucleus. Under normal conditions, mu-opioid receptor (MOR) activation in the LC tonically inhibits LC firing, suppressing norepinephrine release. When opioids are withdrawn, this inhibition is abruptly removed, resulting in a dramatic increase in LC neuronal firing and an outpouring of norepinephrine centrally and peripherally — producing the characteristic autonomic storm. Clonidine exploits a parallel inhibitory pathway: as an alpha-2 adrenergic agonist, it activates presynaptic and somatodendritic alpha-2 receptors on LC neurons, directly suppressing their firing rate and reducing norepinephrine release by a mechanism independent of opioid receptors. This effectively recapitulates part of the inhibitory tone that opioids normally provide, attenuating the autonomic manifestations of withdrawal without activating opioid receptors.

• Option A: Option A is incorrect because clonidine has no opioid receptor activity; it is a pure adrenergic agonist with no mu-opioid receptor pharmacology.
• Option B: Option B is incorrect because clonidine's primary site of antihypertensive and anti-withdrawal action is central (alpha-2 receptors in the LC and vasomotor centers in the brainstem), not peripheral alpha-1 adrenergic receptor blockade; blockade of alpha-1 receptors is the mechanism of prazosin and related alpha-1 antagonists.
• Option C: Option C is incorrect because calcium channel inhibition is not the mechanism of clonidine; this mechanism is associated with gabapentinoids (pregabalin, gabapentin) which target voltage-gated calcium channel alpha-2-delta subunits.
• Option D: Option D is incorrect because clonidine does not act at GABA-B receptors; that mechanism describes baclofen, a GABA-B receptor agonist used in some contexts for alcohol and opioid withdrawal adjunctive therapy.

ANSWER: B

Rationale:

The correct answer is B. Lofexidine was approved by the FDA in 2018 as the first non-opioid medication specifically indicated for the management of opioid withdrawal symptoms in adults — a regulatory distinction that clonidine, which is used off-label for this purpose, does not hold. Pharmacologically, both agents are alpha-2 adrenergic agonists that suppress locus coeruleus noradrenergic hyperactivity during withdrawal. The key pharmacological difference lies in receptor subtype selectivity: clonidine has relatively non-selective activity across alpha-2 receptor subtypes, including the peripheral alpha-2B receptors that mediate vasodilation and the hypotensive effect. Lofexidine has greater selectivity for the alpha-2A subtype, which is predominantly expressed centrally and mediates the sympatholytic (antihypertensive and anti-withdrawal) effects, with lower affinity for peripheral alpha-2B receptors. This selectivity profile results in a clinically meaningful reduction in hypotension compared to clonidine, making lofexidine more appropriate for patients who are intolerant of clonidine-induced blood pressure reduction.

• Option A: Option A is incorrect and inverts the pharmacological reality — lofexidine produces less, not more, hypotension than clonidine precisely because of its receptor subtype selectivity.
• Option C: Option C is incorrect because lofexidine has no mu-opioid receptor activity; its mechanism is entirely adrenergic, and it does not directly suppress opioid craving through opioid receptor pharmacology.
• Option D: Option D is incorrect because the difference between lofexidine and clonidine is not simply dose-dependent; the improved blood pressure profile reflects receptor subtype selectivity, not merely a lower dose.
• Option E: Option E is incorrect because lofexidine's FDA approval is based on clinical trial data demonstrating efficacy for opioid withdrawal symptoms, and its pharmacological selectivity confers a genuine and clinically meaningful safety advantage over off-label clonidine use.

ANSWER: D

Rationale:

The correct answer is D. The Clinical Opiate Withdrawal Scale (COWS) is the validated standard instrument for quantifying opioid withdrawal severity in clinical settings. It is a clinician-administered scale that combines objective findings (resting pulse rate, pupil size, piloerection, diaphoresis, tremor) with observed or reported subjective symptoms (restlessness, bone and joint aches, rhinorrhea or tearing, gastrointestinal (GI) upset including nausea, vomiting, or diarrhea, yawning, and anxiety or irritability). Each of the eleven items is scored on an ordinal scale, and the sum classifies withdrawal severity: mild (5–12), moderate (13–24), moderate-severe (25–36), and severe (above 36). Beyond severity classification and monitoring, the COWS score serves a specific gatekeeping function in buprenorphine induction: the standard threshold of a COWS score of 8–12 or greater ensures that sufficient endogenous opioid receptor displacement has occurred before buprenorphine is administered, minimizing the risk of precipitated withdrawal.

• Option A: Option A is incorrect because the COWS is not a vital-signs-only instrument; it specifically incorporates opioid withdrawal-specific signs such as pupil size, piloerection, yawning, and GI symptoms that are not captured by standard vital sign monitoring.
• Option B: Option B is incorrect on both counts: the COWS includes objective clinician-assessed components (it is not purely subjective), and its applications extend well beyond methadone dose timing — it is used for buprenorphine induction gating, withdrawal severity monitoring, and pharmacological treatment decisions across all opioid withdrawal management contexts.
• Option C: Option C is incorrect because the COWS measures withdrawal manifestations, not sedation or respiratory depression; it is not designed to detect over-sedation from agonist therapy, which is assessed by separate sedation scales such as the Ramsay or RASS (Richmond Agitation-Sedation Scale).
• Option E: Option E is incorrect because the COWS and the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) assess entirely different withdrawal syndromes with different physiological signatures; they are not interchangeable. The CIWA-Ar is specific to alcohol withdrawal and does not assess the opioid-specific signs — rhinorrhea, piloerection, pupil dilation, GI cramping — that appear on the COWS.

ANSWER: C

Rationale:

The correct answer is C. Clonidine's mechanism of action — alpha-2 adrenergic agonism reducing central sympathetic outflow — produces peripheral vasodilation and decreased heart rate as its primary hemodynamic effects. While this is beneficial in the context of the hypertension and tachycardia of opioid withdrawal, the same mechanism carries the risk of excessive hypotension, particularly in patients who are volume-depleted from the diarrhea, vomiting, and diaphoresis of active withdrawal. The standard clinical hold parameter for clonidine in opioid withdrawal management is a pre-dose systolic blood pressure below 90 mmHg. This patient's systolic of 86 mmHg meets the hold criterion, and administering the scheduled dose would risk further reduction in systemic vascular resistance, potentially precipitating syncope, falls, or end-organ hypoperfusion in an already symptomatic patient. The appropriate response is to withhold the dose, notify the physician, provide oral or IV fluid rehydration, and reassess blood pressure before the next scheduled dose.

• Option A: Option A is incorrect because the standard clonidine hold parameter is based on blood pressure, not heart rate; tachycardia during opioid withdrawal is expected and does not independently trigger a clonidine hold.
• Option B: Option B is incorrect because the established hold parameter uses systolic blood pressure below 90 mmHg as the threshold — not diastolic pressure below 60 mmHg; while diastolic hypotension is clinically relevant, the standard operating criterion for clonidine hold in withdrawal protocols is the systolic threshold.
• Option D: Option D is incorrect because a specific blood pressure threshold — systolic below 90 mmHg — is the established objective parameter for clonidine hold decisions; subjective dizziness alone, without a blood pressure check, is an insufficient basis for this clinical decision.
• Option E: Option E is incorrect because the clonidine hold parameter applies regardless of whether the patient is receiving concurrent opioid agonist therapy; the hypotensive risk of clonidine is not exclusive to the combination with methadone, and the hold criterion is a universal safety measure in all withdrawal protocols using clonidine.